SureTrader SureTrader
Home > Boards > Canadian > Medical - Drugs >

iCo Therapeutics (ICOTF)

ICOTF RSS Feed
Add ICOTF Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 8/9/2016 1:25:09 PM - Followers: 13 - Board type: Free - Posts Today: 0
 

Jun 9, 2014
iCo Therapeutics Announces Top-Line Primary Endpoint Data from iCo-007 Phase 2 iDEAL Study in Diabetic Macular Edema
May 29, 2014
iCo Therapeutics Announces First Quarter 2014 Financial Results
Apr 29, 2014
iCo Therapeutics Announces Poster Presentation at ARVO

View All News (+)

 

Company

Overview

iCo Therapeutics Inc. (ICO: TSX-V, ICOTF:OTCQX) is a biotechnology company. By focusing efforts on development instead of research, iCo's business model aims to acquire the rights to drugs that are either off-patent, currently approved or near commercialization and develop them by redosing or reformulating them for new or expanded labels. Management strength is supported by an impressive group of Directors and Advisors.

There is a significant decrease in development risk associated with targeting existing drugs, including:

  • Reduced risk of adverse events since clinical testing and systemic use in humans has already been established.
  • Scale-up and manufacturing issues have already been addressed since clinical grade material has been made.
  • The target and mechanism of action has been identified.

 

iCo-007

iCo Therapeutics is developing iCo-007, a second generation antisense inhibitor targeting C-raf kinase messenger ribonucleic acid (mRNA), for the treatment of retinal neovascular diseases such as diabetic retinopathy (including diabetic macular edema). These conditions are characterized by new blood vessel growth and increased vascular permeability. Drug products that prevent the growth of new blood vessels and inhibit increased vascular permeability may have the potential to treat neovascular diseases, including diabetic retinopathy and diabetic macular edema.  Read More +

iCo-008

iCo-008 (also known as Bertilimumab or CAT-213) is a human immunoglobulin monoclonal antibody targeting eotaxin-1, a member of the chemokine family of proteins, that acts as messenger molecules between the cells of the immune system.

Eotaxin-1 is released by various cells, including eosinophils, epithelial cells, fibroblasts, endothelial cells, T-lymphocytes, monocytes and macrophages. During an allergic response the levels of eotaxin-1 are elevated. This attracts eosinophils, a type of white blood cell, into tissues where they can degranulate causing tissue damage that occurs in a variety of allergic disorders. This condition, known as eosinophilia, can occur in a number of disorders, such as allergic ocular disease of conjunctiva and cornea (conjunctivitis and keratoconjunctivitis), asthma, allergic rhinitis, atopic dermatitis, and other inflammatory disorders, such as inflammatory bowel disease and Crohn's disease.  Read More +

Oral Amphotericin B Delivery System

iCo Therapeutics owns the worldwide exclusive rights to an oral Amphotericin B delivery system for life-threatening infections. The drug delivery technology also has the potential to reprofile other IV administered drugs to the oral route of administration.

Amphotericin B (AmpB), the gold standard for systemic antifungal drugs, is one example of a well established, highly efficacious systemic antifungal drug that has a 50 year history of intravenous therapy. AmpB formulated as a micellar dispersion (Fungizone® FZ) for IV use, remains one of the most effective agents in the treatment of systemic fungal infections, yet no oral formulations are currently commercially availableRead More +

 

Alliances & Global Licensing

Partnering

iCo is actively looking to identify and acquire the rights to products that have a previous clinical history with potential for ophthalmic uses. iCo then employs various drug delivery technologies, re-doses or reformulates these existing products in order to enable ocular administration and gain additional intellectual property coverage for the product. This strategy enables partners to maximize the value of their existing assets with minimal risk of cross use / cross pricing issues.

iCo Therapeutics is currently engaged in partnership arrangements with organizations that include Isis Pharmaceuticals, MedImmune, Immune Pharmaceuticals, AstraZeneca and the University of British Columbia.

iCo Therapeutics acquired the exclusive, world-wide rights from partner Isis Pharmaceuticals Inc., to develop and commercialize iCo-007 for all disease indications. 

iCo has a research collaboration agreement with JDRF, the worldwide leader for research to cure, treat, and prevent type 1 diabetes (T1D), to support the previously announced Phase 2 investigator sponsored clinical trial investigating iCo-007 in Diabetic Macular Edema (DME).

From partner MedImmune (a division of Astra Zeneca), iCo Therapeutics acquired the exclusive, world-wide rights to develop and commercialize iCo-008 for all disease indications.  In 2010, iCo granted Immune Pharmaceuticals an option to an exclusive license for the development and commercialization rights to the systemic uses of iCo-008. Immune Pharmaceuticals licensed the systemic rights to iCo-008 in June 2011. iCo retained worldwide exlcusive rights to all ocular applications of iCo-008.  The partnership with the University of British Columbia resulted in the acquisition of the exclusive, worldwide rights to a novel oral formulation for Amphotericin B to be used for potential systemic fungal and parasitic infections.    



Investor Relations

iCo was awarded a Gold Leaf Award as the Early Stage Company of the Year from BIOTECanada and is a Canada's Top 10™ Competition winner.  

iCo trades on the TSX Venture Exchange under the symbol "ICO", and the OTCQX under the symbol “ICOTF”.

Contacts:

iCo Finance: John Meekison, CFO.  604-602-9414 meekison@icotherapeutics.com

Equicom Group: Michael Moore, Investor Relations 858-886-7813 mmoore@tmxequicom.com

Fact Sheets

Corporate Fact sheet

iCo-007 Fact sheet

iCo-008 Fact sheet

Oral Amphotericin B Delivery System Fact sheet


ICOTF Security Details
Share Structure
Market Value1 $5,067,463 a/o Jun 13, 2014
Shares Outstanding 84,457,713 a/o May 29, 2014
Float 62,821,290 a/o Nov 21, 2013
Authorized Shares Unlimited a/o Nov 21, 2013
Par Value No Par Value
http://www.otcmarkets.com/stock/ICOTF/profile


Shareholders
Shareholders of Record Not Available
Non US Stock Exchange Listing
ICO - TSX Venture Exchange - Qualified
 


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ICOTF
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ICOTF News: iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 06/26/2015 04:00:00 PM
ICOTF News: Immune Pharmaceuticals Initiates Phase II Clinical Trials With Bertilimumab In Ulcerative Colitis And Bullous Pemphigoid 06/25/2015 04:30:00 PM
ICOTF News: Immune Pharmaceuticals Expands Immuno-Dermatology Development Portfolio With Topical Nano-Formulated Cyclosporine A 06/10/2015 08:00:00 AM
ICOTF News: iCo Therapeutics Announces First Quarter 2015 Financial Results 05/28/2015 05:00:00 PM
ICOTF News: Immune Pharmaceuticals to present at Sachs Immuno-Oncology Business Development (BD&L) and Investment Forum in Chicago and at... 05/27/2015 04:30:00 PM
PostSubject
#124   Just got a new Frankfurt listing http://www.teletrader.com/ico-therapeuticsnew- rootbound 08/09/16 01:25:09 PM
#123   Just got a new Frankfurt listing http://www.teletrader.com/ico-therapeuticsnew- rootbound 08/09/16 01:25:07 PM
#122   $imnp Immune Pharmaceuticals Expands Immuno-Dermatology Development Portfolio Wi ListenToMe 06/10/15 09:23:11 AM
#121   ICOTF IS THE NEXT JIDG WATCH AND LEARN! ListenToMe 06/08/15 02:47:26 PM
#120   Everyone should vote to remove all these executives ListenToMe 06/05/15 07:38:24 PM
#119   nibble, nibble.... better get in before the volume ListenToMe 06/04/15 10:05:54 AM
#118   ICOTF is a real co. with real products... ListenToMe 06/01/15 09:09:09 AM
#117   For starters... look at this... ListenToMe 05/29/15 12:06:05 PM
#116   Yes, so you keep telling us. Do you woodstock135 05/29/15 09:16:17 AM
#115   ICOTF volume starting to pick up... Must be ListenToMe 05/28/15 01:36:37 PM
#114   Imnp is on a roll... icotf will benefit greatly. ListenToMe 05/27/15 06:20:47 PM
#113   Our time is near! ...ICOTF is about to ListenToMe 05/26/15 05:21:21 PM
#112   For the cdn listing ICO I just want Kgs68 05/25/15 02:34:39 PM
#111   ICOTF @ a Nickel....is a no brainer!!! ListenToMe 05/22/15 11:21:59 AM
#110   Immune Pharmaceuticals Inc. (Nasdaq: IMNP) to Ring The ListenToMe 05/22/15 10:31:31 AM
#109   IMNP & ICOTF.... Better load up on them ListenToMe 05/22/15 09:52:58 AM
#108   IMNP is on fire! ... ICOTF will follow!!! ListenToMe 05/20/15 02:38:59 PM
#107   Immune Pharmaceuticals IMNP Reports First Quarter 2015 Financial ListenToMe 05/18/15 09:01:39 AM
#106   ICOTF seems to be working on many projects ListenToMe 05/16/15 06:31:35 AM
#105   SSSHHHHH.... Watch icotf Break-Out Big! ListenToMe 05/11/15 12:38:29 PM
#104   http://www.icotherapeutics.com/pipeline/ ListenToMe 05/10/15 08:35:08 AM
#103   ICOTF is about to "catch a Wave" So ListenToMe 05/08/15 11:27:13 AM
#102   NEW YORK and CAMBRIDGE, Mass., May 4, 2015 ListenToMe 05/05/15 07:37:25 AM
#101   Get ready people!! ListenToMe 05/04/15 09:37:34 AM
#100   4/27/2015 ...ICOTF... filing ListenToMe 04/27/15 07:47:01 PM
#99   inical benefits." IN The Mouth Of Madness 04/27/15 06:38:19 PM
#98   I'll tell you all 1 thing... These ICOTF ListenToMe 04/27/15 12:37:06 PM
#97   I second that. ICOTF IS ON IT'S WAY UP! ListenToMe 04/27/15 05:31:50 AM
#96   nice one IN The Mouth Of Madness 04/26/15 07:24:20 PM
#95   LOADING THE BOAT!!!... ICOTF ListenToMe 04/24/15 09:43:22 AM
#94   ICOTF... in it to win it!! ListenToMe 04/24/15 09:37:24 AM
#93   ATTN. ..PHARMA & BIOTECH is and Will Be ListenToMe 04/23/15 04:03:56 PM
#92   Well.... I added more today! ICOTF is going ListenToMe 04/23/15 03:51:39 PM
#91   IMNP is going UP... ICOTF is going UP... ListenToMe 04/23/15 03:49:15 PM
#90   MM's are getting their shares now. Smart buyers ListenToMe 04/23/15 01:42:56 PM
#89   We're up to 9 MM's now for icotf. ListenToMe 04/23/15 11:16:30 AM
#88   A little gap filling is solid. Builds a ListenToMe 04/23/15 10:00:46 AM
#87   When the volume pick up... it's ALLL ABBOOAARRDD!!! ListenToMe 04/23/15 09:45:12 AM
#86   I believe we will have a slow but ListenToMe 04/23/15 09:38:19 AM
#85   Clear .11s and should move quick, looking for Fugu 04/23/15 09:33:51 AM
#84   This is not a 1 day runner.... ICOTF ListenToMe 04/23/15 09:24:02 AM
#83   WHAT??? ... We have a GAPPER!!!??? .10 is ListenToMe 04/23/15 09:17:58 AM
#82   I believe MM's need shares because ICOTF has ListenToMe 04/23/15 09:15:56 AM
#81   bid .09 ask .10 pre Roy London 04/23/15 09:13:45 AM
#80   Are you watching the MM's... they are going ListenToMe 04/23/15 09:13:35 AM
#79   All indications say BUY BUY BUY!!! ICOTF ListenToMe 04/23/15 09:12:15 AM
#78   ALERT** If you never played any of my ListenToMe 04/23/15 09:04:11 AM
#77   I will be adding more TODAY!... Going ALL ListenToMe 04/23/15 08:47:22 AM
#76   I do believe the "All Time High" will ListenToMe 04/23/15 08:41:24 AM
#75   yep span A is heading up on the weekly...http://stockcharts.com/h-sc/ui?s=ICOTF& Roy London 04/23/15 08:38:26 AM
PostSubject